Work with Cryopreserved, Immunotyped PBMCs

CTL-Europe also offers cryopreserved human PBMCs with pre-defined reactivity for the CEF peptide pools and their individual peptides, as well as HLA class I and II high-resolution haplotype characterization. These cryopreserved PBMCs are useful for assay development, standardization, and as basic laboratory research reagents.

Uncharacterized, Cryopreserved PBMCs:
Cryopreserved PBMCs with more than 90% post-thaw viability with performance comparable to fresh PBMCs.

Advantages of uncharacterized, cryopreserved PBMCs:

• Eliminates unpredictable, cumbersome search to obtain PBMCs from volunteers.
• Circumvents the necessity of obtaining bureaucratic, time consuming governmental permits regarding privacy
• Cells are no longer the limiting factor in experimental design. Obtain up to 10 billion cells from the same donor and same bleed date.
• Multiple sites can use identical samples simultaneously, enabling unprecedented comparability of data.

Characterized, Cryopreserved PBMCs:
Cryopreserved PBMCs with more than 90% post-thaw viability with performance comparable to fresh PBMCs. CTL's immunotyped PBMCs are characterized for immune reactivity to different recall antigens and peptides, HLA-typing, as well as gender, age, and ethnicity.

Advantages of characterized, cryopreserved PBMCs:

• Eliminates unpredictable, cumbersome searches to obtain PBMCs from volunteers.
• Immediate access to a library of pre-characterized PBMCs with established HLA-types and antigen reactivities.
• Circumvents the need to obtain bureaucratic, time-consuming governmental permits regarding privacy.
• Cells are no longer the limiting factor in experimental design. Obtain up to 10 billion cells from the same donor and same bleed date.
• Multiple sites can use identical samples simultaneously, thereby enabling unprecedented comparability of data.